Brief: Dynavax Announces First Participant Dosed In Phase 2 Clinical Trial Evaluating Adjuvanted Plague Vaccine
12/09/2022 14:35
Sept 12 (Reuters) - Dynavax Technologies Corp DVAX.O :
* DYNAVAX ANNOUNCES FIRST PARTICIPANT DOSED IN A PHASE 2
CLINICAL
TRIAL EVALUATING AN ADJUVANTED PLAGUE VACCINE
Source text for Eikon: ID:nPn6QV616a
Further company coverage: DVAX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Dynavax Technologies
See all newsNASDAQ TRADE HALT CONTINUES REASON NOT AVAILABLE AT 03:58 AM
NASDAQ TRADE HALT TRADING HALTED; FOR INFORMATION REQUESTED BY NASDAQ AT 07:50 PM
OneSpaWorld jumps as co poised to join S&P SmallCap index
Sanofi targets high single digit sales growth in 2026, plans share buyback (updated)
Focus: Vaccine makers feel a chill as US Health Secretary Kennedy's rhetoric becomes reality